Potential and Current Use of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Diseases of Aging
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 18 (10) , 717-724
- https://doi.org/10.2165/00002512-200118100-00001
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Neuronal Plasticity: Increasing the Gain in PainScience, 2000
- Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trialThe Lancet, 2000
- Selfotel in Acute Ischemic StrokeStroke, 2000
- Excitotoxins in Neuronal Apoptosis and NecrosisJournal of Cerebral Blood Flow & Metabolism, 1999
- Clinical Experience With Excitatory Amino Acid Antagonist DrugsStroke, 1995
- Actions of redox-related congeners of nitric oxide at the NMDA receptorNeuropharmacology, 1994
- NMDA receptor channels: Subunit-specific potentiation by reducing agentsNeuron, 1994
- Delayed administration of memantine prevents N‐methyl‐D‐aspartate receptor‐mediated neurotoxicityAnnals of Neurology, 1993
- Memantine stimulates inositol phosphates production in neurones and nullifies N-methyl-d-aspartate-induced destruction of retinal neuronesNeurochemistry International, 1992
- gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantineEuropean Journal of Pharmacology: Molecular Pharmacology, 1992